Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1030-1040

  Liu, Shu Guang ^a   Li, Zhi Gang ^a   Cui, Lei ^a   Gao, Chao ^a   Li, Wei Jing ^a   Zhao, Xiao Xi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

methotrexate (MTX); Methylenetetrahydrofolate reductase (MTHFR); polymorphism; toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CANCER RISK; CHILD; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORAL MUCOSAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN TOXICITY; THROMBOCYTOPENIA;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHINA; DRUG TOXICITY; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; INFANT; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SKIN DISEASES; THROMBOCYTOPENIA;

EID: 79957492819     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.563883     Document Type: Article

References (31)

1. Jonsson OG, Kamen BA. Methotrexate and childhood leukemia. Cancer Invest 1991;9:53-60.
2. Djerassi I. High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) rescue: background and rationale. Cancer Chemother Rep 1975;6:3-6.
3. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667-1672. (Pubitemid 24245003)
4. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10: 111-113.
5. Van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-1051. (Pubitemid 28199004)
6. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002;13:1915-1918. (Pubitemid 36040780)
7. Chiusolo P, Reddiconto G, Farina G, et al. MTHFR polymorphisms influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 2007;31:1669-1674. (Pubitemid 350051399)
8. Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexaterelated toxicity and survival. Haematologica 2009;94:1391-1398.
9. Liu JX, Chen JP, Tan W, et al. Association between MTHFR gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:488-492.
10. Huang L, Tissing WJ, de Jonge R, et al. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008;22:1798-1800.
11. Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol 2007;86:609-611. (Pubitemid 47018479)
12. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151-4157. (Pubitemid 46743376)
13. Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005;65:2482-2487. (Pubitemid 40490161)
14. Wu MY, Li CK, Li ZG. Considerations on the treatment strategies of childhood acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi 2010;48:161-165.
15. Ma XL, Wang B, Guo HY, et al. Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi 2010;48:289-292.
16. Karas-Kuzelicki N, Jazbec J, Milek M, et al. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 2009;23:971-974.
17. Arenas M, Simpson G, Lewis CM, et al. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin Chem 2005;51:2371-2373.
18. Cui L, Li Z, Wu M, et al. Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia. Leuk Res 2010;34:1314-1319.
19. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64-68.
20. Solé X, Guinó E, Valls J, et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22: 1928-1929. (Pubitemid 44283043)
21. Seidemann K, Book M, Zimmermann M, et al. MTHFR 677(C-T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM95. Ann Hematol 2006;85:291-300. (Pubitemid 43732651)
22. Costea I, Moghrabi A, Laverdiere C, et al. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006;91: 1113-1116. (Pubitemid 44204780)
23. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C-4T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003;103:294-299. (Pubitemid 36076421)
24. Haagsma C, Blom H, van Riel P, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84. (Pubitemid 29116306)
25. Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997;15:2800-2806. (Pubitemid 27330006)
26. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003;21:3084-3091. (Pubitemid 46606289)
27. Kantar M, Kosova B, Cetingul N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:912-917.
28. Krajinovic M, Lamothe S, Labuda D, et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004;103:252-257. (Pubitemid 38029946)
29. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-190. (Pubitemid 34596782)
30. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007; 52:166-171. (Pubitemid 46188292)
31. Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-3834.